Skip to main content

Solid Biosciences Inc.

SLDB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001707502

No open-market purchases or sales by Solid Biosciences Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.14B in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding Solid Biosciences Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of SLDB: Q3 2021 compared with Q4 2021
MeasureQ3 2021Of which not filed for Q4 2021Q4 2021Change
Holders91182−8
Shares77.0M262.0K75.6M−1.15M (−1.5%)
Value$184.3M$626.0K$132.2M−$51.5M (−28.0%)

1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.

New holders (10)

Institutions that held Solid Biosciences Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to SLDB in Q4 2021
InstitutionSharesValue% of portfolio
Nomura Holdings Inc268,709$470.0K0.00%
Caxton Associates LP177,571$311.0K0.04%
Acadian Asset Management LLC123,406$214.0K0.00%
Bailard, Inc.53,400$93.0K0.00%
Quantum Private Wealth, LLC41,871$73.0K0.03%
ProShare Advisors LLC28,560$49.0K0.00%
Assenagon Asset Management S.A.25,893$45.0K0.00%
Cubist Systematic Strategies, LLC18,715$33.0K0.00%
Two Sigma Securities, LLC11,425$20.0K0.00%
JNBA Financial Advisors8,000$14.0K0.00%

Sold out (18)

Institutions that held Solid Biosciences Inc. at the end of Q3 2021 and filed for Q4 2021 without it.

Not filed for Q4 2021 yet (1)

Institutions that held Solid Biosciences Inc. at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding SLDB in Q3 2021 that haven't filed for Q4 2021
InstitutionShares, Q3 2021Value, Q3 2021
Marshall Wace North America L.P.261,973$626.0K